Search 6,000+ CA Community College Courses

Class Central is learner-supported. When you buy through links on our site, we may earn an affiliate commission.

YouTube

Kidney Cancer Clinical Updates and Research Highlights from 2023

Dana-Farber Cancer Institute via YouTube

Start learning Write review

Overview

Learn about the latest kidney cancer clinical updates from ASCO GU 2023 in a comprehensive conference presentation from Dana-Farber Cancer Institute's Lank Center for Genitourinary Oncology. Explore key findings from multiple clinical trials including the ZIRCON phase 3 study on PET/CT imaging, COSMIC-313 trial examining cabozantinib plus nivolumab and ipilimumab combinations, and the 3-year follow-up results from CheckMate 9ER comparing nivolumab plus cabozantinib versus sunitinib. Gain insights into biomarker analyses, treatment outcomes based on IMDC risk groups, and clinical outcomes for advanced chromophobe renal cell carcinoma patients treated with immunotherapy-based regimens. Examine interim results from the CaboPoint phase 2 study investigating cabozantinib treatment following checkpoint inhibitor therapy, and understand tumor response patterns and subsequent therapy timing for various treatment approaches in advanced renal cell carcinoma management.

Syllabus

Intro
Results from phase 3 study of Zr-DFO-girentuximab for PET/CT imaging of clear cell renal cell carcinoma (ZIRCON)
ZIRCON: Summary
Outcomes by IMDC risk in the COSMIC-313 phase 3 trial evaluating cabozantinib (C) plus nivolumab (N) and ipilimumab (1) in first-line advanced RCC (ARCC) of IMDC intermediate or poor risk.
Baseline characteristics by IMDC risk
PFS by IMDC risk group
Tumor response by IMDC risk
Nivolumab plus cabozantinib vs sunitinib for first-line treatment of advanced renal cell carcinoma (aRCC): 3- year follow-up from the phase 3 CheckMate 9ER trial.
Best overall response by IMDC risk
Time to subsequent therapy for patients completing 2 years of nivolumab
CaboPoint: Interim results from a phase 2 study of cabozantinib after checkpoint inhibitor (CPI) therapy in patients with advanced renal cell carcinoma (RCC)
CaboPoint: Patient characteristics
Interim efficacy analysis
Biomarker analysis from the phase 3 CheckMate 9ER trial of nivolumab + cabozantinib v sunitinib for advanced renal cell carcinoma (aRCC).
Survival states, favorable risk
Characterization of clinical outcomes among patients with advanced chromophobe renal cell carcinoma (ChRCC) treated with first-line immunotherapy (10)-based regimens

Taught by

Dana-Farber Cancer Institute

Reviews

Start your review of Kidney Cancer Clinical Updates and Research Highlights from 2023

Start learning

Never Stop Learning.

Get personalized course recommendations, track subjects and courses with reminders, and more.

Sign up for free
Someone learning on their laptop while sitting on the floor.